Asian Pacific Journal of Tropical Medicine

REVIEW ARTICLE
Year
: 2020  |  Volume : 13  |  Issue : 7  |  Page : 288--294

Biosimilars: A novel perspective in diabetes therapy


Muthu Thiruvengadam1, Baskar Venkidasamy2, Ill-Min Chung1, Prabhu Thirupathi3, Umadevi Subramanian3 
1 Department of Crop Science, College of Sanghuh Life Science, Konkuk University, Seoul 05029, Republic of Korea
2 Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu 641046, India
3 Translational Research Platform for Veterinary Biologicals, Tamil Nadu Veterinary and Animal Sciences University, Madhavaram Milk Colony, Chennai 600051, Tamil Nadu, India

Correspondence Address:
Umadevi Subramanian
Translational Research Platform for Veterinary Biologicals, Tamil Nadu Veterinary and Animal Sciences University, Madhavaram Milk Colony, Chennai 600051, Tamil Nadu
India

Diabetes mellitus, an endocrine disorder, has a wider reach among most of the world population. The incidence of diabetes is high not only among adults but wider-age groups are also becoming susceptible to this disease because of modified food habits and lifestyle changes that are alien to the physiological system. The control of blood glucose level would be the prime focus of all the therapeutic targets, which is achieved through drugs, modified lifestyle, and paleo-based diets. To find a solution to these problems, earlier humans have revolutionized the science with the discovery of insulin from the porcine pancreatic crude extract. Later, developments have been made with artificial recombinant insulin and even insulin analogs that would mimic the physiological basal insulin in controlling the blood sugar levels. Various factors such as cost and logistics for quality delivery to the end-user at various corners of the world have impeded the reach of the original product. Hence, biosimilar insulins that are original insulin analogs were designed to execute similar physiological functions. In the current situation, the use of biosimilars has been approved in various clinical conditions that are very promising in its functions. In the present review, the various developmental phases of biosimilar preparations and the regulations enforced ensuring a quality product in the market through the Food and Drug Administration and the European Medicines Agency have been discussed.


How to cite this article:
Thiruvengadam M, Venkidasamy B, Chung IM, Thirupathi P, Subramanian U. Biosimilars: A novel perspective in diabetes therapy.Asian Pac J Trop Med 2020;13:288-294


How to cite this URL:
Thiruvengadam M, Venkidasamy B, Chung IM, Thirupathi P, Subramanian U. Biosimilars: A novel perspective in diabetes therapy. Asian Pac J Trop Med [serial online] 2020 [cited 2022 Aug 9 ];13:288-294
Available from: https://www.apjtm.org/article.asp?issn=1995-7645;year=2020;volume=13;issue=7;spage=288;epage=294;aulast=Thiruvengadam;type=0